Verrica Pharmaceuticals

NASDAQ VRCA
$5.11 -0.05 -1.07%
Today share price
USA
Sector: Healthcare Industry: Pharmaceuticals
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 18.75 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
41.94M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
53.62M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.46
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
94.84M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
629.29 %

Upcoming events Verrica Pharmaceuticals

All events
No upcoming events scheduled

Stock chart Verrica Pharmaceuticals

Stock analysis Verrica Pharmaceuticals

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-0.64 -1.50
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
-3.68 1.38
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-0.98 -0.54
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
-0.21 0.35
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
355.24 -27.86

Price change Verrica Pharmaceuticals per year

0.41$ 6.82$
Min Max

Summary analysis Verrica Pharmaceuticals

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Verrica Pharmaceuticals

Revenue and net income Verrica Pharmaceuticals

All parameters

About company Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; which has completed phase II clinical trial for treating common warts; and that is in phase II clinical trial for the treatment of external genital warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Address:
44 West Gay Street, West Chester, PA, United States, 19380
Company name: Verrica Pharmaceuticals
Issuer ticker: VRCA
ISIN: US92511W1080
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2018-06-15
Sector: Healthcare
Industry: Pharmaceuticals
Site: https://www.verrica.com